European Rights to AstraZeneca’s Heart Failure Treatment Acquired by Recordati for $300M
CURE Throws Hat into the Pharmaceutical Cannabis Sector
Under Development: CBD Pharmaceutical Chewing Gum
About AXIM® AXIM® Biotechnologies, Inc. focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. The company’s flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. (Source: Globe…
Sanofi Reports 2016 Sales and Business Earnings at Constant Exchange Rate
Alcohol Dependence Drug Exhibits Positive Findings in Study
Alcobra’s ADHD Treatment Misses Primary Endpoint in Phase 3 Trial
Positive Phase 3 Results for GW Pharmaceuticals’ CBD Drug
Study: Positive Results for BioCryst’s Delayed Ebola Treatment
BioCryst Pharmaceuticals, Inc. announced positive results from a proof-of-concept study of its broad spectrum antiviral, BCX4430, for the delayed treatment of Ebola virus infection in rhesus macaques. The goals of this 28-day study were to assess the effect of different dosing regimens of BCX4430 administered by i.m. injection on survival in rhesus macaques with established Ebola…
RedHill BioPharma Partners with the NIH to Create Ebola Treatment
RedHill Biopharma Ltd. announced the signing of a research collaboration agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), intended to evaluate RedHill’s proprietary experimental therapy for the treatment of Ebola virus disease. The new research collaboration follows encouraging results from preliminary non-clinical studies conducted…
Amyris Partners with J&J Innovation for Biosynthetic Drug Discovery
Amyris, Inc. has entered into a research agreement with a commercial license option with Janssen Biotech, Inc., part of Janssen Pharmaceutical Companies. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, the collaboration will use Amyris’s µPharmTM platform technology to develop a customized library of natural and natural-like compounds to test against Janssen’s…
